- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05810922
Arbutus Berry - Intervention Study to Evaluate the Modulation of Intestinal Microbiota and Metabolic Parameters (F4F)
The tree that produces the arbutus berry, the strawberry tree, scientific name Arbutus unedo L., belongs to the family of Ericaceae. It exists in almost all of Southern Europe in arid and siliceous lands, in woods and forests and is very common in Portugal.
Known for its use in the production of liqueurs and brandy, the arbutus berry is a fruit that can be consumed in nature or incorporated in the preparation of other foods. Arbutus berry has been attributed some properties beneficial to health given its low caloric value and its high content of vitamin C and flavonoids, which is why it is considered a good source of antioxidants.
Arbutus has a high carbohydrate content (70-80% dry weight) with a relevant fiber fraction (10-30%), constituting an interesting source of vegetable protein (1-9%) and lipids (2-3%). Given this interesting nutritional composition, the hypothesis is that a daily consumption of this fruit can have an impact in health outcomes such as microbiota modulation and an improvement of metabolic parameters.
Study Overview
Detailed Description
The main objective of this clinical trial is to evaluate the effect of including a daily consumption of arbutus berry on the composition and diversity of the intestinal microbiota. It is also intended to evaluate metabolic parameters to determine the impact of this intervention.
Participants will consume 50g or 200g of arbutus berry daily for 4 weeks. This study aims to provide scientific evidence regarding the impact of arbutus berry consumption on intestinal microbiota and general health improvements.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lisboa, Portugal, 1169-056
- Nova Medical School Universidade Nova de Lisboa
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Caucasian.
- Age between 18 and 50 years.
- Filling informed consent.
- Body mass index (BMI) between 18,5 kg/m2 and 25 kg/m2.
Exclusion Criteria:
- Arbutus berry sensibility.
- Arbutus berry daily consumption in the month before the study begin.
- Having taken antibiotics within the 6 months prior to beginning the study.
- Use of pro/prebiotics or fiber as a dietary supplement or any food/molecule that modifies intestinal transit time 6 weeks before recruitment.
- Use of laxative 6 weeks before recruitment.
- Specific nutritional therapy (e.g. high protein).
- Excessive alcohol consumption.
- Smoking.
- Diagnosis of gastrointestinal pathology, hormonal or thyroid pathology, autoimmune diseases, chronic use of corticosteroids, psychiatric disease or Diabetes Mellitus.
- Use of proton pump inhibitors, antidiabetic drugs, insulin, or statins.
- Pregnant or breastfeeding.
- Participation in another clinical trial within the last 3 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 50 g arbutus berry
consumption of 50 g arbutus berry/day for 14 days
|
consumption of 50 g arbutus berry/day or 200 g arbutus berry/day for 14 days
|
Experimental: 200 g arbutus berry
consumption of 200 g arbutus berry/day for 14 days
|
consumption of 50 g arbutus berry/day or 200 g arbutus berry/day for 14 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in gut microbiota characterization
Time Frame: 14 days
|
Difference in gut microbiota taxonomic characterization, from baseline to the end of intervention
|
14 days
|
Changes in gut microbiota diversity
Time Frame: 14 days
|
Difference in gut microbiota Shannon index, from baseline to the end of intervention
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in fasting glucose
Time Frame: 14 days
|
Changes in fasting glucose, measured in mg/dL, from baseline to end of intervention
|
14 days
|
Changes in HOMA-IR
Time Frame: 14 days
|
Changes in HOMA-IR from baseline to end of intervention
|
14 days
|
Changes in total cholesterol
Time Frame: 14 days
|
Changes in total cholesterol, measured in mg/dL, from baseline to end of intervention
|
14 days
|
Changes in LDL cholesterol
Time Frame: 14 days
|
Changes in LDL cholesterol, measured in mg/dL, from baseline to end of intervention
|
14 days
|
Changes in high sensitivity PCR
Time Frame: 14 days
|
Changes in high sensitivity PCR, measured in mg/dL, from baseline to end of intervention
|
14 days
|
Changes in HDL cholesterol
Time Frame: 14 days
|
Changes in HDL from baseline to end of intervention
|
14 days
|
Changes in IL-6
Time Frame: 14 days
|
Changes in IL-6, measured in pg/mL, from baseline to end of intervention
|
14 days
|
Changes in IL-10
Time Frame: 14 days
|
Changes in IL-10, measured in pg/mL, from baseline to end of intervention
|
14 days
|
Changes in TNFa
Time Frame: 14 days
|
Changes in TNFa, measured in pg/mL, from baseline to end of intervention
|
14 days
|
Changes in adiponectin
Time Frame: 14 days
|
Changes in adiponectin, measured in ng/mL, from baseline to end of intervention
|
14 days
|
Changes in leptin
Time Frame: 14 days
|
Changes in leptin, measured in ng/mL, from baseline to end of intervention
|
14 days
|
Changes in triglycerides
Time Frame: 14 days
|
Changes in triglycerides, measured in mg/dL, from baseline to end of intervention
|
14 days
|
Changes in short chain fatty acids amount in the stool
Time Frame: 14 days
|
Changes in short chain fatty acids in the stool, measured in ng/g fecal sample, from baseline to end of intervention
|
14 days
|
Changes in alkaline phosphatase activity in the stool
Time Frame: 14 days
|
Changes in alkaline phosphatase activity in the stool, measured in xx/xx, from baseline to end of intervention
|
14 days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- F4F- Forest for Future
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diet Habit
-
University of Rhode IslandCompletedDiet Modification | Diet HabitUnited States
-
University of ReadingActive, not recruitingDiet Modification | Diet, Healthy | Diet HabitUnited Kingdom
-
NYU Langone HealthRecruitingDiet HabitUnited States
-
University of ReadingUniversity of PlymouthEnrolling by invitation
-
NYU Langone HealthNational Institute on Aging (NIA)Completed
-
The University of Tennessee, KnoxvilleCompleted
-
The University of Tennessee, KnoxvilleCompleted
-
University of California, DavisNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...Completed
-
University of VictoriaCompleted
Clinical Trials on arbutus berry
-
Northumbria UniversityThe New Zealand Institute for Plant and Food ResearchCompletedAgeingUnited Kingdom
-
SeppicCompleted
-
Aventure ABBerry Lab ABCompletedAge-related Cognitive DeclineSweden
-
Shin Kong Wu Ho-Su Memorial HospitalUnknownIncrease the Eradication Rate of Helicobacter PyloriTaiwan
-
University of LouisvilleJames Graham Brown Cancer CenterTerminated
-
Northumbria UniversityThe New Zealand Institute for Plant and Food ResearchCompleted
-
Northumbria UniversityThe New Zealand Institute for Plant and Food ResearchCompletedHealthyUnited Kingdom
-
Northumbria UniversityThe New Zealand Institute for Plant and Food ResearchCompleted
-
Natural Immune Systems IncUnknownStem Cell Mobilization | Hematopoietic Stem Cell Mobilization | Stem Cell HomingUnited States
-
Finnish Institute for Health and WelfareUniversity of Oslo; Academy of Finland; The Finnish Funding Agency for Technology... and other collaboratorsCompletedInflammation | Blood Pressure | Platelet FunctionFinland